🇺🇸 FDA
Patent

US 11926676

Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such

granted A61KA61K2039/505A61K2039/5156

Quick answer

US patent 11926676 (Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such) held by CRISPR THERAPEUTICS AG expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/5156, A61K2039/5158, A61K2239/31